Israel - English - Ministry of Health

medison pharma ltd - ataluren - granules for oral suspension - ataluren 250 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

Israel - English - Ministry of Health

medison pharma ltd - lanreotide acetate - powder and solvent for suspension for injection - lanreotide acetate 0.03 g/vial - lanreotide - lanreotide - treatment of acromegaly (when the treatment of growth hormone is not normalized after surgery and/or radiotherapy). treatment of the clinical symptoms of carcinoid tumors (after a test injection). treatment of primary thyrotropic adenomas responsible for hypethyroidism as a preparation for / or as a complement to surgery and/or radiotherapy or where these therapies are unsuitable.

Israel - English - Ministry of Health

medison pharma ltd - peginterferon beta 1a - solution for injection - peginterferon beta 1a 125 mcg / 0.5 ml - peginterferon beta-1a - plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis

Israel - English - Ministry of Health

medison pharma ltd - peginterferon beta 1a - solution for injection - peginterferon beta 1a 63 mcg / 0.5 ml - peginterferon beta-1a - plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis

Israel - English - Ministry of Health

medison pharma ltd - peginterferon beta 1a - solution for injection - peginterferon beta 1a 94 mcg / 0.5 ml - peginterferon beta-1a - plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis

Israel - English - Ministry of Health

medison pharma ltd - interferon beta 1a - solution for injection - interferon beta 1a 30 mcg / 0.5 ml - interferon beta-1a - interferon beta-1a - treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of mri abnormalities characteristic of ms and if they are determined to be at high risk of developing clinically definite multiple sclerosis. safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

Israel - English - Ministry of Health

medison pharma ltd - lomitapide as mesylate - capsules - lomitapide as mesylate 10 mg - lomitapide - an adjunct to a low-fat diet and other lipid-lowering treatments, including ldl apheresis where available, to reduce low-density lipoprotein cholesterol (ldl-c), total cholesterol (tc), apolipoprotein b (apo b), and non-high-density lipoprotein cholesterol (non-hdl-c) in patients with homozygous familial hypercholesterolemia (hofh).

Israel - English - Ministry of Health

medison pharma ltd - lomitapide as mesylate - capsules - lomitapide as mesylate 20 mg - lomitapide - an adjunct to a low-fat diet and other lipid-lowering treatments, including ldl apheresis where available, to reduce low-density lipoprotein cholesterol (ldl-c), total cholesterol (tc), apolipoprotein b (apo b), and non-high-density lipoprotein cholesterol (non-hdl-c) in patients with homozygous familial hypercholesterolemia (hofh).

Israel - English - Ministry of Health

medison pharma ltd - lomitapide as mesylate - capsules - lomitapide as mesylate 5 mg - lomitapide - an adjunct to a low-fat diet and other lipid-lowering treatments, including ldl apheresis where available, to reduce low-density lipoprotein cholesterol (ldl-c), total cholesterol (tc), apolipoprotein b (apo b), and non-high-density lipoprotein cholesterol (non-hdl-c) in patients with homozygous familial hypercholesterolemia (hofh).

Israel - English - Ministry of Health

medison pharma ltd - cabozantinib as (s) malate - film coated tablets - cabozantinib as (s) malate 20 mg - cabozantinib - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for advanced renal cell carcinoma- as first-line treatment of adult patients with intermediate or poor risk, per imdc criteria.- in adults following prior vascular endothelial growth factor (vegf)-targeted therapy.cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc), in adults with child-pugh class a hepatic impairment who have previously been treated with sorafenib.differentiated thyroid carcinoma (dtc)cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (dtc), refractory or not eligible to radioactive iodine (rai) who have progressed during or after prior systemic therapy.